Induction of interferon-γ-inducible protein 10 by SARS-CoV infection, interferon alfacon 1 and interferon inducer in human bronchial epithelial Calu-3 cells and BALB/c mice

Antiviral Chemistry and Chemotherapy

Volumn 20, Issue 4, 2010, Pages 169-177

  Kumaki, Yohichi ^a   Day, Craig W ^a   Bailey, Kevin W ^a   Wandersee, Miles K ^a   Wong, Min Hui ^a   Madsen, Jason R ^a   Madsen, Justin S ^a   Nelson, Nathan M ^a   Hoopes, Justin D ^a   Woolcott, John D ^a   McLean, Tyler Z ^a   Blatt, Lawrence M ^b   Salazar, Andres M ^c   Smee, Donald F ^a   Barnard, Dale L ^a  

^a UTAH STATE UNIVERSITY   (United States)

^b InterMune Inc   (United States)

^c Oncovir Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CONSENSUS INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; BRONCHUS MUCOSA; CELL LINE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARS CORONAVIRUS; TREATMENT RESPONSE; VIRUS INHIBITION; VIRUS PNEUMONIA; VIRUS REPLICATION; VIRUS TITRATION;

ANIMALS; CARBOXYMETHYLCELLULOSE; CHEMOKINE CXCL10; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; FEMALE; HUMANS; INTERFERON INDUCERS; INTERFERON TYPE I, RECOMBINANT; LUNG; MICE; MICE, INBRED BALB C; POLY I-C; POLYLYSINE; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SPECIFIC PATHOGEN-FREE ORGANISMS; VIRUS REPLICATION;

EID: 77949689342     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1477     Document Type: Article

References (41)

1. Murphy PM. The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol 1994; 12:593-633.
2. Strader CD, Fong TM, Tota MR, Underwood D, Dixon RA. Structure and function of G protein-coupled receptors. Annu Rev Biochem 1994; 63:101-132.
3. Kobilka B. Adrenergic receptors as models for G proteincoupled receptors. Annu Rev Neurosci 1992; 15:87-114.
4. Premack BA, Schall TJ. Chemokine receptors: gateways to inflammation and infection. Nat Med 1996; 2:1174-1178.
5. Wells TN, Power CA, Lusti-Narasimhan M, et al. Selectivity and antagonism of chemokine receptors. J Leukoc Biol 1996; 59:53-60.
6. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol 1997; 15:675-705.
7. Groneberg DA, Witt C, Wagner U, Chung KF, Fischer A. Fundamentals of pulmonary drug delivery. Respir Med 2003; 97:382-387.
8. Groneberg DA, Fischer A, Chung KF, Daniel H. Molecular mechanisms of pulmonary peptidomimetic drug and peptide transport. Am J Respir Cell Mol Biol 2004; 30:251-260.
9. Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 2004; 136:95-103.
10. Jiang Y, Xu J, Zhou C, et al. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am J Respir Crit Care Med 2005; 171:850-857.
11. Sauty A, Dziejman M, Taha RA, et al. The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J Immunol 1999; 162:3549-3558.
12. Spiegel M, Weber F. Inhibition of cytokine gene expression and induction of chemokine genes in non-lymphatic cells infected with SARS coronavirus. Virol J 2006; 3:17.
13. Yen YT, Liao F, Hsiao CH, Kao CL, Chen YC, Wu-Hsieh BA. Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro. J Virol 2006; 80:2684-2693.
14. Barnard DL, Day CW, Bailey K, et al. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir Chem Chemother 2006; 17:275-284.
15. Kumaki Y, Day CW, Wandersee MK, et al. Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells. Biochem Biophys Res Commun 2008; 371:110-113.
16. Tseng CT, Tseng J, Perrone L, Worthy M, Popov V, Peters CJ. Apical entry and release of severe acute respiratory syndrome-associated coronavirus in polarized Calu-3 lung epithelial cells. J Virol 2005; 79:9470-9479.
17. Mossel ECHC, Narayanan K, Makino S, Tesh RB, Peters CJ. Exogenous ACE2 expression allows refractory cell lines to support severe acute respiratory syndrome coronavirus replication. J Virol 2005; 79:3846-3850.
18. Day CW, Baric R, Cai SX, et al. A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo. Virology. 2009, 395:210-222.
19. Altrock BW, Fagin KD, Hockman HR, et al. Antiviral and antitumor effects of a human interferon analog, IFNalpha Con 1, assessed in hamsters. J Interferon Res 1986; 6:405-415.
20. Alberti A. Interferon alfacon-1: a novel interferon for the treatment of chronic hepatitis C. BioDrugs 1999; 12:343-357.
21. Gowen BB, Wong MH, Jung KH, Blatt LM, Sidwell RW. Prophylactic and therapeutic intervention of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with interferon alfacon-1. Antiviral Res 2008; 77:215-224.
22. Julander JG, Morrey JD, Blatt LM, Shafer K, Sidwell RW. Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model. Antiviral Res 2007; 73:140-146.
23. Morrey JD, Day CW, Julander JG, Blatt LM, Smee DF, Sidwell RW. Effect of interferon-alpha and interferoninducers on West Nile virus in mouse and hamster animal models. Antivir Chem Chemother 2004; 15:101-109.
24. Wong SS, Yuen KY. The management of coronavirus infections with particular reference to SARS. J Antimicrob Chemother 2008; 62:437-441.
25. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Treatment of SARS with human interferons. Lancet 2003; 362:293-294.
26. Paragas J, Blatt LM, Hartmann C, Huggins JW, Endy TP. Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models. Antiviral Res 2005; 66:99-102.
27. Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 2003; 290:3222-3228.
28. Blatt LM, Davis JM, Klein SB, Taylor MW. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res 1996; 16:489-499.
29. Thompson AB, Robbins RA, Romberger DJ, et al. Immunological functions of the pulmonary epithelium. Eur Respir J 1995; 8:127-149.
30. Cinatl J, Jr., Hoever G, Morgenstern B, et al. Infection of cultured intestinal epithelial cells with severe acute respiratory syndrome coronavirus. Cell Mol Life Sci 2004; 61:2100-2112.
31. de Lang A, Baas T, Teal T, et al. Functional genomics highlights differential induction of antiviral pathways in the lungs of SARS-CoV-infected macaques. PLoS Pathog 2007; 3:e112.
32. Christen U, Benke D, Wolfe T, et al. Cure of prediabetic mice by viral infections involves lymphocyte recruitment along an IP-10 gradient. J Clin Invest 2004; 113:74-84.
33. Stephen EL, Sammons ML, Pannier WL, Baron S, Spertzel RO, Levy HB. Effect of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys (Macaca mulatta). J Infect Dis 1977; 136:122-126.
34. Levy HB, London W, Fuccillo DA, Baron S, Rice J. Prophylactic control of simian hemorrhagic fever in monkeys by an interferon inducer, polyriboinosinicpolyribocytidylic acid-poly-L-lysine. J Infect Dis 1976; 133 Suppl:A256-A259.
35. Harrington DG, Hilmas DE, Elwell MR, Whitmire RE, Stephen EL. Intranasal infection of monkeys with Japanese encephalitis virus: clinical response and treatment with a nuclease-resistant derivative of poly (I).poly (C). Am J Trop Med Hyg 1977; 26:1191-1198.
36. Baer GM, Shaddock JH, Moore SA, Yager PA, Baron SS, Levy HB. Successful prophylaxis against rabies in mice and Rhesus monkeys: the interferon system and vaccine. J Infect Dis 1977; 136:286-291.
37. Kende M, Lupton HW, Rill WL, Levy HB, Canonico PG. Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice. Antimicrob Agents Chemother 1987; 31:986-990.
38. Levy HB, Baer G, Baron S, et al. A modified polyriboinosinic- polyribocytidylic acid complex that induces interferon in primates. J Infect Dis 1975; 132:434-439.
39. Wong JP, Christopher ME, Salazar AM, Dale RM, Sun LQ, Wang M. Nucleic acid-based antiviral drugs against seasonal and avian influenza viruses. Vaccine 2007; 25:3175-3178.
40. Taylor MW, Grosse WM, Schaley JE, et al. Global effect of PEG-IFN-alpha and ribavirin on gene expression in PBMC in vitro. J Interferon Cytokine Res 2004; 24:107-118.
41. Sanda C, Weitzel P, Tsukahara T, et al. Differential gene induction by type I and type II interferons and their combination. J Interferon Cytokine Res 2006; 26:462-472.